These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11673754)

  • 1. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
    Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
    Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Reinalter SC; Jeck N; Brochhausen C; Watzer B; Nüsing RM; Seyberth HW; Kömhoff M
    Kidney Int; 2002 Jul; 62(1):253-60. PubMed ID: 12081585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
    Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
    J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective cyclooxygenase-2 inhibition by nimesulide in man.
    Cullen L; Kelly L; Connor SO; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cyclooxygenases and prostanoid receptorsin furosemide-like salt losing tubulopathy: the hyperprostaglandin E syndrome.
    Nüsing RM; Seyberth HW
    Acta Physiol Scand; 2004 Aug; 181(4):523-8. PubMed ID: 15283766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Nüsing RM; Treude A; Weissenberger C; Jensen B; Bek M; Wagner C; Narumiya S; Seyberth HW
    J Am Soc Nephrol; 2005 Aug; 16(8):2354-62. PubMed ID: 15976003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.
    Llinás MT; López R; Rodríguez F; Roig F; Salazar FJ
    Am J Physiol Renal Physiol; 2001 Nov; 281(5):F975-82. PubMed ID: 11592955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
    Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
    Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
    Stichtenoth DO; Marhauer V; Tsikas D; Gutzki FM; Frölich JC
    Kidney Int; 2005 Nov; 68(5):2197-207. PubMed ID: 16221219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
    Belton OA; Duffy A; Toomey S; Fitzgerald DJ
    Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
    Khan AA; Brahim JS; Rowan JS; Dionne RA
    Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
    Haas NA; Nossal R; Schneider CH; Lewin MA; Ocker V; Holder M; Uhlemann F
    Pediatr Crit Care Med; 2003 Apr; 4(2):249-51. PubMed ID: 12749662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
    Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprostaglandin E syndrome: use of indomethacin and steroid, and death due to necrotizing enterocolitis and sepsis.
    Cetinkaya M; Köksal N; Ozkan H; Dönmez O; Sağlam H; Kiriştioğlu I
    Turk J Pediatr; 2008; 50(4):386-90. PubMed ID: 19014056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
    Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
    Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis.
    Foitzik T; Hotz HG; Hotz B; Wittig F; Buhr HJ
    Hepatogastroenterology; 2003; 50(52):1159-62. PubMed ID: 12846004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of increased prostacyclin production in Bartter's syndrome by indomethacin.
    Güllner HG; Cerletti C; Bartter FC; Gill JR; Smith JB
    Trans Assoc Am Physicians; 1980; 93():130-40. PubMed ID: 7018063
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.
    de Leval X; Dogné JM; Neven P; Labasse A; Delarge J; Reginster JY; Henrotin Y
    J Pharm Belg; 1999; 54(3):89-90. PubMed ID: 10431478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.